Overview

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.
Phase:
PHASE1
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.